Last Week Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings

May 17, 2018 - By Alice Fox

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.16. That’s change of 0.19, from 2017Q3’s 1.35. 7 investors sold all, 12 reduced holdings as Regulus Therapeutics Inc. ratio is negative. 12 rose holdings while 10 funds amassed holdings. Funds hold 53.17 million shares thus 9.64% less from 2017Q3’s 58.85 million shares.
Victory Capital Inc reported 327,770 shs. Northern Trust has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 187,492 shs. D E Shaw Commerce Incorporated owns 27,319 shs. Wells Fargo And Mn invested in 0% or 392,142 shs. Meeder Asset Mngmt reported 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Mariner Wealth Advsr Ltd Com has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Savings Bank Of Mellon holds 0% or 36,752 shs. Ascend Cap Ltd Liability Com invested in 1.01M shs or 0.04% of the stock. State Street Corp holds 47,869 shs or 0% of its capital. Barclays Pcl reported 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). South Dakota Council has invested 0.04% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Drw Lc invested in 0.01% or 100,000 shs. Renaissance Technology Limited Liability invested in 0% or 137,589 shs. Royal Financial Bank Of Canada owns 109,607 shs. Deutsche Bank & Trust Ag accumulated 98 shs.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

In total 5 analysts cover Regulus (NASDAQ:RGLS). “Buy” rating has 2, “Sell” are 0, while 3 are “Hold”. 40% are bullish. 8 are the (NASDAQ:RGLS)’s analyst reports since December 11, 2017 according to StockzIntelligence Inc. On Monday, March 12 the company was maintained by Wedbush. On Thursday, March 8 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Market Perform” rating given by BMO Capital Markets. On Tuesday, March 27 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Hold” rating given by FBR Capital. On Thursday, February 8 the firm has “Buy” rating by Wedbush given. On Wednesday, December 20 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given by Wedbush. On Monday, December 11 Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) with “Buy” rating. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On
20/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
11/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain

Ticker’s shares touched $0.71 during the last trading session after 0.07% change.Since May 17, 2017 it’s 52.76% down thus downtrending. The stock underperformed the S&P 500 by 64.31%.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The firm is worth $74.07 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Currently it has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Another two news for Regulus Therapeutics Inc. (NASDAQ:RGLS) were briefly released by: Globenewswire.com on May 17, 2018 with title “Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global …”. The other Seekingalpha.com‘s article was titled “Regulus Therapeutics’ (RGLS) CEO Joseph Hagan on Q1 2018 Results – Earnings Call Transcript” and released on May 11, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.